Sobi to list bond loan on NASDAQ OMX Stockholm and publishes
Sobi to list bond loan on NASDAQ OMX Stockholm and publishes prospectus
STOCKHOLM, SWEDEN -- (Marketwire) -- 11/12/12 -- On 26 June 2012 Swedish Orphan Biovitrum AB (Sobi) issued a 5-year senior unsecured bond loan in the total amount of SEK 600 million. Sobi has applied for a listing of the bond loan on NASDAQ OMX Stockholm in accordance with the terms and conditions of the bond loan and prepared a prospectus.
The prospectus has been approved by the Swedish Financial Supervisory Authority and the bond loan is expected to be listed on NASDAQ OMX Stockholm on 16 November 2012. The prospectus is now available on Sobi's webpage http://www.sobi.com/Investors--Media/Bond-Loan/
Swedish Orphan Biovitrum (Sobi)
Sobi is an international healthcare company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within hemophilia and neonatology. Sobi also markets more than 40 products for companies in the specialty and rare disease space. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 12 November, 2012 at 12:45 p.m. CET.
Sobi Press Release on November 12, 2012 in pdf format: http://hugin.info/134557/R/1657011/535846.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
For further information, please contact: Asa Stenqvist Vice President, Head of Communications and Investor Relations (Interim) Tel.: +46 8 697 21 88